Gene therapy for heart problems in Duchenne muscular dystrophy
Part of Bones, joints & muscles, Genetic & congenital, Heart & circulation clinical trials.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Duchenne muscular dystrophy (confirmed by genetic test).
- You have a weak heart with scarring in at least 3 areas of the main pumping chamber.
- Your heart's pumping ability (ejection fraction) is less than 40%.
- You have been on a stable heart medication and steroid treatment for at least 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called SGT-003 for children with Duchenne muscular dystrophy. It aims to help the body produce a working version of dystrophin, the protein missing in Duchenne.
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
This trial tests a gene therapy called GNR-097 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help improve muscle function, and the study will check how safe and effective it is.
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Hear when a new DMD-Associated Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.